IMNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunome Inc (IMNM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, a bolstered balance sheet extending its runway to 2028, and multiple potential catalysts in oncology. Despite weak financial performance in Q4 2025, the company's strategic execution and commercial transition provide a solid foundation for long-term growth.
The technical indicators show a bullish trend with SMA_5 > SMA_20 > SMA_200. MACD is above 0 and positively contracting, indicating upward momentum. RSI is neutral at 68.987, and the stock is trading near its first resistance level (R1: 23.358).
Strong analyst support with multiple Buy ratings and price targets ranging from $30 to $
Bolstered balance sheet extending cash runway to
Upcoming NDA for varegacestat and multiple ADC catalysts.
Hedge funds significantly increasing their positions (577.15% increase in buying).
Weak Q4 2025 financial performance with revenue dropping to 0 and net income declining by 12.90% YoY.
Lack of recent news or significant insider trading activity.
In Q4 2025, the company reported a revenue drop to 0 (-100% YoY), net income of -$69.9M (-12.90% YoY), and an EPS decline to -0.74 (-42.19% YoY). Gross margin remained stable at 100%.
Analysts are optimistic with multiple Buy ratings and price targets ranging from $30 to $40. Analysts highlight the company's strategic execution, commercial transition, and strong balance sheet as key positives.
